Zhejiang Huahai Pharmaceutical Co Ltd (Huahai Pharmaceuticals) develops and markets active pharmaceutical ingredients (APIs), intermediates, and formulations. It carries out the commercial production of captopril, enalapril, and lisinopril.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Huahai Pharmaceutical has undertaken various research and development (R&D) initiatives, including the development of innovative R&D systems, process development systems, and clinical research systems. The company focuses on API R&D through entities like Shanghai Kesheng Pharmaceutical R&D Co Ltd and Aobo Biopharmaceutical Technology (Hubei) Co Ltd, and formulation R&D through Huawu Biopharmaceutical Technology (Hubei) Co Ltd and others. The company is also advancing its technology platforms, such as transdermal patches and multi-specific antibody platforms, to enhance its R&D competitiveness. The US R&D unit leads the exchange of pharmaceutical technology intelligence and product registration with the US FDA, while the Shanghai R&D unit focuses on patentable know-how and biopharmaceutical R&D. The Linhai R&D unit leads API manufacturing improvements and formulation process development. In FY2024, the company incurred R&D expenses of CNY1,200.2 million, which, as a percentage of revenue, stood at 12.6% and grew 22% YoY. As of December 2024, the company obtained 65 new patent authorizations, including 49 in China and 16 overseas; and filed 194 new patent applications, including 119 in China, 51 overseas, and 24 PCT applications. It had a total of 664 patents, including 532 in China and 132 overseas.